Blood tests for diagnosing and tracking brain diseases and mental disorders
Looks back at blood markers in adults with dementia or mental disorders.
Plain-language title generated from the registry record
Registry title: Retrospective Observational Study of Blood-based Biomarkers in the Diagnosis and Monitoring of Patients With a Neurodegenerative Disease or Mental Disorder
Key facts
- Where
- Barcelona, SpainSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a brain disease such as Alzheimer's, Parkinson's or other dementia, or with a mental disorder such as depression, bipolar disorder or schizophrenia. Healthy volunteers also take part as controls.
- Age
- Over 18 years
- Sex
- All
- Earlier treatment
- Cannot have had chemotherapy that may harm nerves or radiotherapy to the head.
- Biomarker or test result
- Blood-based biomarkers are studied. Controls must have no Alzheimer's or other brain disease markers.
Main reasons for not taking part
- No neuropsychological test data
- Taking blood thinners such as warfarin, heparin or apixaban
- Drug abuse in the last year
- Cancer affecting the central nervous system, unless in complete remission for 5 years or longer
- Alzheimer's diagnosis with markers that do not fit Alzheimer's disease
Read by machine on 9 November 2026.
Where in Spain
- Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau - IIB Sant PauBarcelona, SpainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- Trial code
- NCT07314190
- Record updated
- 23 February 2026
- Original description
This is a retrospective observational study to evaluate the clinical utility of blood-based biomarkers in the diagnosis and management of patients with a neurodegenerative disease (ND) or mental disorder (MD).Read full original descriptionShow less
Synapsing Retrospective Biomarker Study
This is a retrospective observational study to evaluate the clinical utility of blood-based biomarkers in the diagnosis and management of patients with a neurodegenerative disease (ND) or mental disorder (MD).
Inclusion: Age>18 and donation of blood,; full clinical and psychological assessment; Available neuroimaging is optional as not all patients are suitable; Age and sex-matched unaffected volunteers without a MD or ND diagnosis are used as controls; Unaffected controls are usually spouses or children of patients that are informed about our studies at each clinical site.
Exclusion: anticoagulant treatment such as acenocoumarol, heparin, warfarin, dabigatran, rivaroxaban, apixaban, drug abuse in the last year,; the patient has received potentially neurotoxic chemotherapy and/or patient has received cranial radiotherapy; medical history of cancer affecting the central nervous system that has not been in complete remission for 5 years or longer,; Clinical diagnosis of Alzheimer's disease where pathophysiological markers (measured in CSF or plasma) are inconsistent with Alzheimer's disease pathophysiology; Cognitively healthy volunteers where pathophysiological markers (measured in CSF or plasma) are consistent with Alzheimer's disease or other neurodegenerative pathophysiology; Lack of neuropsychological data,.